Five-session prostate radiation better preserves bowel quality of life, trial finds

Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) with moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate-risk prostate cancer indicate that SBRT improved bowel health-related quality of life (HRQOL) in this patient population. There was no significant improvement with SBRT in the other primary objectives, including urinary HRQOL and disease-free survival. These results are now published in the JAMA following their presentation during the Plenary Session of the 2025 American Society for Radiation Oncology Annual Meeting in San Francisco.

Read it at Medical Xpress ↗

← Front page